Cidofovir + Probenecid

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus Retinitis

Conditions

Cytomegalovirus Retinitis, HIV Infections

Trial Timeline

— → —

NCT ID

NCT00002142

About Cidofovir + Probenecid

Cidofovir + Probenecid is a pre-clinical stage product being developed by Gilead Sciences for Cytomegalovirus Retinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00002142. Target conditions include Cytomegalovirus Retinitis, HIV Infections.

What happened to similar drugs?

6 of 20 similar drugs in Cytomegalovirus Retinitis were approved

Approved (6) Terminated (3) Active (11)

❌mRNA-1647ModernaPhase 3

🔄ASP0113 + PlaceboAstellas PharmaPhase 3

🔄Letermovir tablet + Letermovir IVMerckPhase 3

✅LetermovirMerckApproved

🔄Letermovir + PlaceboMerckPhase 3

🔄LetermovirMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002142	Pre-clinical	Completed	—	—	Cytomegalovirus Retinitis
NCT00000799	Pre-clinical	Completed	—	Apr 1, 1996	Cytomegalovirus Retinitis
NCT00002437	Phase 2	Completed	—	—	Cytomegalovirus Retinitis
NCT01816646	Phase 1	Completed	Sep 1, 2013	Dec 1, 2016	Blood And Marrow Transplantation

Competing Products

20 competing products in Cytomegalovirus Retinitis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40